Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

patient expectations

- PMLiVE

Lucid Group announces the appointment of a new Legal and Compliance manager

Lucid Group demonstrates continual investment in its infrastructure by appointing Sebastian Goodwin as its new Legal and Compliance manager.Sebastian studied politics and trained to be a lawyer before moving into...

Lucid Group Communications Limited

- PMLiVE

Lucid Group Experience the Magic of Mindfulness, Meditation and Massage

This time of year can be busier than normal. Lucid Group understand the importance of taking some time out to relax and unwind. That's why yesterday, relaxation, meditation and mindfulness...

Lucid Group Communications Limited

- PMLiVE

Merck’s Keytruda picks up third approval for NSCLC in China

New indication as a first-line treatment in combination with chemotherapy

- PMLiVE

AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER

Updated draft evidence report maintains the benefit is small with higher price tag

- PMLiVE

New faces at Lucid Group and ZPB Associates

Latest movers in healthcare comms

- PMLiVE

ChemoCentryx surges on phase 3 vasculitis study

Shares in the US biotech rose 227% after announcing trial results

- PMLiVE

Q&A: Vicky Bramham

PME interviews OPEN Health Patient & Brand Communications' managing director, PR

Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....

OPEN Health

- PMLiVE

Bedrock’s on fire for Wellbeing Week

Bedrock creates a positive working environment to enable individuals and our business to thrive.

Bedrock Healthcare Communications

- PMLiVE

CymaBay Therapeutics plummets after abandoning NASH drug

Failure of mid-stage liver disease candidate caused shares to slip over 75%

- PMLiVE

FDA backs GBT’s sickle cell drug Oxbryta

Second new treatment for blood disorder to be approved this year

Teva Pharma logo

Teva among generic drugmakers hoping to settle US antitrust probe

A number of companies are accused of colluding on drug prices

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links